![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/26/2935381/0/en/Cartesian-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html
https://www.globenewswire.com/news-release/2024/08/08/2926791/0/en/Cartesian-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/08/07/2926326/0/en/Cartesian-Therapeutics-Announces-New-Employment-Inducement-Grants.html
https://www.globenewswire.com/news-release/2024/07/08/2909941/0/en/Cartesian-Therapeutics-Announces-New-Employment-Inducement-Grants.html
https://www.fiercebiotech.com/biotech/cartesian-claims-phase-2b-autoimmune-car-t-win-after-changing-endpoint-removing-patients
https://www.globenewswire.com/news-release/2024/07/02/2907781/0/en/Cartesian-Therapeutics-Strengthens-Board-of-Directors-with-Appointment-of-Kemal-Malik.html
https://www.globenewswire.com/news-release/2024/07/02/2907275/0/en/Cartesian-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Trial-of-Descartes-08-in-Systematic-Lupus-Erythematosus.html
https://www.globenewswire.com/news-release/2024/07/02/2907274/0/en/Cartesian-Therapeutics-Announces-130-Million-Private-Placement-Equity-Financing.html
https://www.globenewswire.com/news-release/2024/07/02/2907273/0/en/Cartesian-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2b-Trial-of-Descartes-08-in-Patients-with-Myasthenia-Gravis.html